Abstract:
:By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest, highest-risk patients. Despite the limitations of the data used for risk adjustment, there are potential solutions to improve the accuracy of these codes by calibrating data by merging databases and compiling information collected for multiple reporting programs to improve accuracy. In addition, healthcare staff should be informed about the importance of risk adjustment for quality of care assessment and reimbursement. As the number of encounters tied to value-based reimbursements increases in inpatient and outpatient care, coupled with accurate data collection and utilization, the methods used for risk adjustment could be expanded to better account for differences in the care delivered in diverse settings.
journal_name
Expert Rev Pharmacoecon Outcomes Resjournal_title
Expert review of pharmacoeconomics & outcomes researchauthors
Al Kazzi ES,Hutfless Sdoi
10.1586/14737167.2015.1083864subject
Has Abstractpub_date
2015-01-01 00:00:00pages
873-6issue
6eissn
1473-7167issn
1744-8379journal_volume
15pub_type
社论abstract:BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2019.1632194
更新日期:2020-06-01 00:00:00
abstract:INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1080/14737167.2018.1392241
更新日期:2018-02-01 00:00:00
abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2017.1282316
更新日期:2017-08-01 00:00:00
abstract:OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2020.1782748
更新日期:2020-07-20 00:00:00
abstract:AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,meta分析
doi:10.1586/14737167.2016.1165609
更新日期:2016-12-01 00:00:00
abstract::The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/erp.11.45
更新日期:2011-08-01 00:00:00
abstract:OBJECTIVE:This systematic review and meta-analysis aimed to reassess the effectiveness of condoms in reducing heterosexual transmission of HIV. METHODS:Medline, Scopus, and the ISI Web of Science databases were searched up to June 2014. Eligible studies were synthesized using random-effects models. RESULTS:Twenty-fiv...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,meta分析,评审
doi:10.1586/14737167.2016.1102635
更新日期:2016-08-01 00:00:00
abstract:OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2015.1065734
更新日期:2015-01-01 00:00:00
abstract::Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.13.7
更新日期:2013-04-01 00:00:00
abstract::Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.4.1.99
更新日期:2004-02-01 00:00:00
abstract::Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.6.677
更新日期:2005-12-01 00:00:00
abstract:BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2017.1375407
更新日期:2018-04-01 00:00:00
abstract::Smoking cessation is the only strategy that has shown a lasting reduction in the decline of lung function in patients with chronic obstructive pulmonary disease. This study aims to evaluate the cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease, to assess the q...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2015.1001976
更新日期:2015-04-01 00:00:00
abstract::The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2017.1256775
更新日期:2017-04-01 00:00:00
abstract::Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.7.2.137
更新日期:2007-04-01 00:00:00
abstract:INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1080/14737167.2017.1385395
更新日期:2017-12-01 00:00:00
abstract:AIMS:To quantify the relationship between the timing of gastroesophageal reflux disease (GERD) symptoms and the burden of illness. PATIENTS & METHODS:Data from the 2010 National Health and Wellness Survey were used. Regression analyses compared non-GERD controls with GERD patients with diurnal symptoms, nocturnal symp...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/erp.11.72
更新日期:2011-12-01 00:00:00
abstract::Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.11.14
更新日期:2011-04-01 00:00:00
abstract::The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.3.5.561
更新日期:2003-10-01 00:00:00
abstract:OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2018.1384696
更新日期:2018-04-01 00:00:00
abstract::The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.894462
更新日期:2014-04-01 00:00:00
abstract::This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2014.927315
更新日期:2014-10-01 00:00:00
abstract::We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2013.838027
更新日期:2013-10-01 00:00:00
abstract::Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.4.423
更新日期:2005-08-01 00:00:00
abstract:INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1080/14737167.2019.1536549
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.2015.1081061
更新日期:2016-01-01 00:00:00
abstract::Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/14737167.2016.1135740
更新日期:2016-01-01 00:00:00
abstract::Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章,评审
doi:10.1586/erp.12.85
更新日期:2013-02-01 00:00:00
abstract::Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.5.6.783
更新日期:2005-12-01 00:00:00
abstract::Osteoporosis is a public health threat to approximately 44 million individuals in the USA, or 55% of men and women over the age of 50 years. The primary goal of osteoporosis management is to prevent fracture, the most devastating consequence. Risk factors and bone mineral density can be assessed to determine appropria...
journal_title:Expert review of pharmacoeconomics & outcomes research
pub_type: 杂志文章
doi:10.1586/14737167.6.5.525
更新日期:2006-10-01 00:00:00